Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Immunotherapy has prompted a dramatic change in the management of head and neck squamous cell carcinoma (HNSCC), but the percentage of patients benefiting from treatment is limited to 20% or less. The application of precision oncology to HNSCC introduces the potential for the emergen...

Descripción completa

Detalles Bibliográficos
Autores principales: Burcher, Kimberly M., Lantz, Jeffrey W., Gavrila, Elena, Abreu, Arianne, Burcher, Jack T., Faucheux, Andrew T., Xie, Amy, Jackson, Clayton, Song, Alexander H., Hughes, Ryan T., Lycan, Thomas, Bunch, Paul M., Furdui, Cristina M., Topaloglu, Umit, D’Agostino, Ralph B., Zhang, Wei, Porosnicu, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616373/
https://www.ncbi.nlm.nih.gov/pubmed/34830888
http://dx.doi.org/10.3390/cancers13225733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616373/
https://www.ncbi.nlm.nih.gov/pubmed/34830888
http://dx.doi.org/10.3390/cancers13225733

Ejemplares similares